Oculus Biomed Pty Ltd ("OBM"; "The company") is an innovative biomedical company based in Melbourne, Australia, established in 2016. Currently, OBM has 4 employees at Melbourne and generates $6.11 million in sales (USD). The company is mainly engaged in research, development, and commercialisation for new drugs and medical devices for eye-related diseases. With professional ophthalmological and medical experts on board, OBM combines Taiwanese and Australian biomedical research resources, international clinical development experiences and competitive commercialization skills.

 

The company has created an expanding portfolio of patent-protected projects which will be transformed into products approved by the regulatory bodies of other countries. OBM owns the exclusive global commercialisation rights to the new drug development for the treatment of certain eye diseases, including age-related macular degeneration (AMD) and dry eye diseases (DEDs). In addition，OBM is developing a specially processed cornea that will effectively help the treatment of Lamellar Keratoplasty, Corneal Ulcers, and Pterygium.

​

Eureka TechIN recognizes the R&D capabilities of OBM and is very confident in the prospects within the growing ophthalmic and biomedical market. In October of 2019, Eureka TechIN became a shareholder of OBM and boost it to explore the bigger Asian market and practice its motto of “Vision Your Health”.